Leerink Partnrs Analysts Boost Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Stock analysts at Leerink Partnrs raised their Q4 2024 earnings per share estimates for Hims & Hers Health in a report released on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.07. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.16 EPS, FY2026 earnings at $0.67 EPS and FY2027 earnings at $0.99 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) earnings per share.

HIMS has been the subject of a number of other reports. Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler restated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and an average price target of $21.00.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $23.44 on Wednesday. The firm has a 50 day simple moving average of $18.22 and a 200 day simple moving average of $18.26. The company has a market cap of $5.03 billion, a price-to-earnings ratio of 53.27 and a beta of 1.06. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the transaction, the insider now directly owns 169,935 shares in the company, valued at $3,935,694.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 650,659 shares of company stock worth $11,712,198 over the last quarter. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royce & Associates LP grew its stake in Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the period. Victory Capital Management Inc. grew its position in Hims & Hers Health by 164.9% in the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after purchasing an additional 32,108 shares during the period. WealthPlan Investment Management LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at $1,042,000. Versor Investments LP acquired a new position in Hims & Hers Health during the third quarter worth $634,000. Finally, Los Angeles Capital Management LLC raised its holdings in Hims & Hers Health by 40.8% during the third quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company’s stock worth $743,000 after buying an additional 11,686 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.